Comparative Pharmacology
Head-to-head clinical analysis: LINAGLIPTIN versus TRADJENTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINAGLIPTIN versus TRADJENTA.
LINAGLIPTIN vs TRADJENTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
5 mg orally once daily
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours, allowing once-daily dosing. No accumulation at steady state.
Clinical Note
moderateLinagliptin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Delavirdine
"The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Clarithromycin
"The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin."
Clinical Note
moderateLinagliptin + Ranolazine
Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition.
Approximately 90% of absorbed dose is excreted unchanged in feces (biliary/fecal route), and about 5% is excreted unchanged in urine. Renal excretion is minimal (<1% as metabolites).
Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor
"The serum concentration of Ranolazine can be increased when it is combined with Linagliptin."